GSA Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

GSA Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	+6,293	New	+$349K	0.02%	1166
2024 Q4	–	Sell	-37,308	Closed	-$1.47M	–	2080
2024 Q3	$1.47M	Buy	37,308 +30,830	+476%	+$1.24M	0.11%	232
2024 Q2	$253K	Sell	6,478 -15,136	-70%	-$605K	0.02%	1361
2024 Q1	$930K	Buy	+21,614	New	+$994K	0.07%	480
2023 Q2	–	Sell	-18,562	Closed	-$664K	–	1992
2023 Q1	$664K	Buy	18,562 +4,799	+35%	+$177K	0.07%	540
2022 Q4	$543K	Buy	+13,763	New	+$501K	0.07%	553
2016 Q2	–	Sell	-13,384	Closed	-$94K	–	1946
2016 Q1	$94K	Sell	13,384 -24,407	-65%	-$175K	0.01%	1587
2015 Q4	$304K	Sell	37,791 -28,150	-43%	-$241K	0.01%	1455
2015 Q3	$545K	Buy	65,941 +32,697	+98%	+$325K	0.03%	1079
2015 Q2	$383K	Buy	33,244 +20,944	+170%	+$290K	0.01%	1490
2015 Q1	$207K	Buy	+12,300	New	+$227K	0.01%	1913

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GSA Capital Partners's XENE Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 6,293 shares worth $380K. The stake represents 0.02% of the portfolio and ranks #1166 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in XENE as recently as Q3 2024.

GSA Capital Partners first reported a position in XENE in Q1 2015 and has held it in 11 quarters since. The position peaked at $1.47M in Q3 2024. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

GSA Capital Partners held 6,293 shares of Xenon Pharmaceuticals worth $380K as of Q2 2026.
Xenon Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
Xenon Pharmaceuticals made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1166 holding.
GSA Capital Partners first reported a position in Xenon Pharmaceuticals in Q1 2015 and has held it in 11 quarters since.
GSA Capital Partners's Xenon Pharmaceuticals position peaked at $1.47M in Q3 2024.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.